CCG
ABBV icon

Cypress Capital Group’s AbbVie ABBV Stock Holding History

Cypress Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24M Sell
110,435
-2,179
-2% -$483K 2.7% 4
2025
Q4 		$25.7M Buy
112,614
+4,661
+4% +$1.06M 2.88% 4
2025
Q3 		$25M Sell
107,953
-517
-0.5% -$105K 2.99% 4
2025
Q2 		$20.1M Buy
108,470
+878
+0.8% +$163K 2.51% 7
2025
Q1 		$22.5M Sell
107,592
-4,754
-4% -$924K 2.95% 6
2024
Q4 		$20M Sell
112,346
-1,451
-1% -$267K 2.45% 6
2024
Q3 		$22.5M Sell
113,797
-134
-0.1% -$25K 2.53% 5
2024
Q2 		$19.5M Sell
113,931
-928
-0.8% -$154K 2.34% 6
2024
Q1 		$20.9M Buy
114,859
+3,938
+4% +$679K 2.51% 6
2023
Q4 		$17.2M Sell
110,921
-1,061
-0.9% -$155K 2.24% 6
2023
Q3 		$16.7M Sell
111,982
-640
-0.6% -$94K 2.41% 6
2023
Q2 		$15.2M Sell
112,622
-3,859
-3% -$566K 2.19% 6
2023
Q1 		$18.6M Sell
116,481
-8,739
-7% -$1.34M 2.85% 4
2022
Q4 		$20.2M Buy
125,220
+5,598
+5% +$858K 3.05% 5
2022
Q3 		$16.1M Sell
119,622
-5,396
-4% -$774K 2.68% 5
2022
Q2 		$19.1M Sell
125,018
-5,711
-4% -$873K 2.92% 5
2022
Q1 		$21.2M Buy
130,729
+10,260
+9% +$1.49M 2.61% 4
2021
Q4 		$16.3M Sell
120,469
-14,352
-11% -$1.7M 2.04% 6
2021
Q3 		$14.5M Buy
134,821
+2,250
+2% +$257K 1.98% 9
2021
Q2 		$14.9M Sell
132,571
-21
-0% -$2.37K 2.02% 9
2021
Q1 		$14.3M Sell
132,592
-2,187
-2% -$234K 2.04% 9
2020
Q4 		$14.4M Sell
134,779
-3,048
-2% -$293K 2.17% 6
2020
Q3 		$12.1M Sell
137,827
-1,510
-1% -$142K 2.01% 8
2020
Q2 		$13.7M Buy
139,337
+6,206
+5% +$546K 2.51% 5
2020
Q1 		$10.1M Sell
133,131
-576
-0.4% -$49.1K 2.34% 8
2019
Q4 		$11.8M Sell
133,707
-647
-0.5% -$53.7K 2.11% 9
2019
Q3 		$10.2M Sell
134,354
-16,205
-11% -$1.11M 1.96% 8
2019
Q2 		$10.9M Sell
150,559
-172
-0.1% -$13.5K 2.16% 7
2019
Q1 		$12.1M Buy
150,731
+1,098
+0.7% +$89.8K 2.49% 4
2018
Q4 		$13.8M Sell
149,633
-1,536
-1% -$135K 3.16% 2
2018
Q3 		$14.3M Buy
151,169
+5,858
+4% +$556K 2.71% 4
2018
Q2 		$13.5M Buy
145,311
+1,604
+1% +$157K 2.78% 3
2018
Q1 		$13.6M Sell
143,707
-180
-0.1% -$19.8K 2.85% 2
2017
Q4 		$13.9M Sell
143,887
-5,200
-3% -$490K 2.9% 3
2017
Q3 		$13.2M Sell
149,087
-2,252
-1% -$171K 2.82% 3
2017
Q2 		$11M Sell
151,339
-1,797
-1% -$121K 2.43% 4
2017
Q1 		$9.98M Sell
153,136
-5,275
-3% -$332K 2.33% 6
2016
Q4 		$9.92M Sell
158,411
-1,468
-0.9% -$89.6K 2.36% 6
2016
Q3 		$10.1M Sell
159,879
-2,125
-1% -$138K 2.41% 6
2016
Q2 		$10M Buy
162,004
+1,449
+0.9% +$88.3K 2.35% 7
2016
Q1 		$9.17M Sell
160,555
-7,485
-4% -$417K 2.25% 9
2015
Q4 		$9.96M Sell
168,040
-4,272
-2% -$246K 2.4% 6
2015
Q3 		$9.38M Buy
172,312
+160
+0.1% +$10.4K 2.31% 6
2015
Q2 		$11.6M Buy
172,152
+324
+0.2% +$21.2K 2.66% 1
2015
Q1 		$10.1M Buy
171,828
+5,532
+3% +$334K 2.29% 4
2014
Q4 		$10.9M Sell
166,296
-2,503
-1% -$158K 2.52% 3
2014
Q3 		$9.75M Sell
168,799
-1,667
-1% -$92.5K 2.32% 5
2014
Q2 		$9.62M Sell
170,466
-76
-0% -$3.99K 2.26% 5
2014
Q1 		$8.77M Buy
170,542
+5,119
+3% +$259K 2.15% 6
2013
Q4 		$8.74M Sell
165,423
-12,336
-7% -$606K 2.15% 4
2013
Q3 		$7.95M Sell
177,759
-5,381
-3% -$239K 1.97% 8
2013
Q2 		$7.57M Buy
+183,140
New +$8.01M 1.58% 12

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cypress Capital Group's ABBV Position: Q1 2026 in Review

Cypress Capital Group reduced its AbbVie (ABBV) stake by 1.9% in Q1 2026, selling an estimated $483K and leaving 110,435 shares worth $24M. The position accounts for 2.7% of the portfolio, ranked #4.

Cypress Capital Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.7M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cypress Capital Group held 110,435 shares of AbbVie worth $24M as of Q1 2026.
  • Cypress Capital Group sold 2,179 AbbVie shares in Q1 2026, an estimated $483K.
  • AbbVie made up 2.7% of Cypress Capital Group's portfolio in Q1 2026, its #4 holding.
  • Cypress Capital Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Cypress Capital Group's AbbVie position peaked at $25.7M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cypress Capital Group's 13F filing for Q1 2026, filed 15 May 2026.